Guideline Backs First-Line Anti-PD-1/L1 Therapy in NSCLC

]]>(MedPage Today) -- Updated clinical guidance for advanced non-small cell lung cancer (NSCLC) provided additional support for first-line treatment with a PD-1/L1 inhibitor in the absence of driver mutations.Single-agent pembrolizumab (Keytruda...